Tag:

biosimilars

Latest Headlines

Latest Headlines

Amgen's $4.5B in Q1 sales lags estimates, thanks to slow-selling Enbrel

Amgen reported a mixed bag of results in the first earnings period following its acquisition of Onyx Pharmaceuticals. First-quarter revenues came in approximately $230 million lower than consensus, a miss that the company attributes primarily to sluggish sales of Enbrel.

Big Pharma tries to short-circuit France's move toward biosimilar substitution

Late last year, French legislators quietly slipped a measure into the country's 2014 budget legislation that would allow pharmacists to substitute inexpensive biosimilar drugs for pricier biotech brands. While not a full-out assault on branded biologics, it would make France the first European country to substitute the cheaper drugs, and the pharma industry is doing everything it can to derail that move before France's Administrative Supreme Court decrees it into effect.

Hospira wins Herceptin patent suit in U.K., paving way for biosim

Hospira is one step closer to selling a Herceptin biosimilar in Britain. The U.S.-based drugmaker persuaded a U.K. court to overturn two Roche patents on the drug. And that means, as of now, Herceptin (trastuzumab) could be open to biosim competition when its main patent expires July 28.

Kyowa Hakko Kirin finishes $60M biologics API plant

Japanese drugmaker Kyowa Hakko Kirin, which develops its own drugs and is in a partnership with Fuji to make biosimilars, has completed construction on a new active pharmaceutical plant for biologics.

Novartis names two new leaders to growth drivers Alcon, Sandoz

Novartis, amid a company-wide strategic review, has said some of its underperforming units may be on the way out. But as it draws up its blueprints for the future, it's also working to bolster its star businesses, and Wednesday it announced some changes at the top of two of its key divisions.

India's Lupin queues up for a share of the biosimilar boom

With some of its larger rivals already at work on biotech knockoffs, Indian drugmaker Lupin is on the hunt for partners to help shepherd it into the biosimilar fray, taking aim at top-selling treatments soon to come off patent.

AbbVie, Amgen and Roche most vulnerable to biosim rivals, Moody's says

As the biosimilar market takes shape, companies are gunning to produce copies of some of the world's top-selling drugs. And according to a new Moody's report, with their star products wearing targets on their backs, AbbVie, Amgen and Roche are most exposed to the new competition.

Sanofi wards off Lilly's Lantus challenger with infringement lawsuit

Sanofi's got the top-selling diabetes drug in the world right now, and it intends to keep it that way. The French drugmaker is suing Eli Lilly over infringement claims on four of the patents for its Lantus insulin product, which is set to lose protection next February.

As biosims win nods in Europe and India, debate over naming rights heats up

What's in a name? In the pharmaceutical world, the answer to this question is no simple matter. Drugmakers, biotechs and their generic rivals are squabbling over the names that will be assigned to biosimilars, in a battle for a marketing edge.

Buzz: A buyer is in talks to acquire a big stake in Celltrion

The buzz about the potential sale of a big stake in Celltrion, Korea's biosimilars developer, picked up after the company filed a statement with regulators indicating that discussions with a potential buyer or buyers are underway.